8-K Announcements
6Material company update
May 26, 2026·SEC
Material company update
May 18, 2026·SEC
Material company update
Apr 15, 2026·SEC
Alaunos Therapeutics, Inc.(TCRT)Earnings, Financials & Key Ratios
TCRT•NASDAQ
Price updated Jun 19, 2026
AboutAlaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.Show more
- Revenue$5K-50.0%
- EBITDA-$4M+12.3%
- Net Income-$4M+10.8%
- EPS (Diluted)-2.20+24.7%
- Gross Margin100%
- EBITDA Margin-84360%-75.4%
- Operating Margin-84500%-75.6%
- Net Margin-83520%-78.5%
- ROE-198.1%-77.2%
TCRT Key Insights
Alaunos Therapeutics, Inc. (TCRT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 44.6%
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 13 (bottom 13%)
- ✗Shares diluted 21.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TCRT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TCRT Price & Volume
Alaunos Therapeutics, Inc. (TCRT) stock price & volume — 10-year historical chart
Loading chart...
TCRT Growth Metrics
Alaunos Therapeutics, Inc. (TCRT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-49.16%
5 Years-
3 Years-88.04%
TTM-70%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-0.93%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.57%
Return on Capital
10 Years-100.03%
5 Years-118.94%
3 Years-153.66%
Last Year-200.43%
TCRT Recent Earnings
Alaunos Therapeutics, Inc. (TCRT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (73%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.59
—
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.40+89.1%
$3.69
Rev
$3,000+0.0%
$3,000
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.55+88.8%
$4.90
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.63+88.2%
$5.33
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.59 | — |
| Q2 2026 | Mar 31, 2026 | $0.40vs $3.69+89.1% | $3,000vs $3,000+0.0% |
| Q4 2025 | Nov 14, 2025 | $0.55vs $4.90+88.8% | — |
| Q3 2025 | Aug 14, 2025 | $0.63vs $5.33+88.2% | — |
Based on last 12 quarters of dataView full earnings history →
TCRT Peer Comparison
Alaunos Therapeutics, Inc. (TCRT) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IOVA | 1.4B | 3.91 | -3.59 | 60.6% | -123.9% | -50.17% | 0.07 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 TCRX | 119.52M | 0.92 | -0.92 | 266.65% | -13.61% | -91.94% | 0.76 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 |
Compare TCRT vs Peers
Alaunos Therapeutics, Inc. (TCRT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TCRT Income Statement
Alaunos Therapeutics, Inc. (TCRT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 6.39M | 146K | 0 | 0 | 398K | 2.92M | 5K | 10K | 5K | 3K |
Revenue Growth % | -6.88% | -97.71% | -100% | - | - | 634.17% | -99.83% | 100% | -50% | -70% |
Cost of Goods Sold | 0 | 0 | 629K | 1.13M | 0 | 0 | 4.8M | 0 | 0 | 193K |
COGS % of Revenue | - | - | - | - | - | - | 96060% | - | - | - |
Gross Profit | 6.39M▲ 0% | 146K▼ 97.7% | -629K▼ 530.8% | -1.13M▼ 79.3% | 398K▲ 135.3% | 2.92M▲ 634.2% | -4.8M▼ 264.2% | 10K▲ 100.2% | 5K▼ 50.0% | -190K▲ 0% |
Gross Margin % | 100% | 100% | - | - | 100% | 100% | -95960% | 100% | 100% | -6333.33% |
Gross Profit Growth % | -6.88% | -97.71% | -530.82% | -79.33% | 135.28% | 634.17% | -264.2% | 100.21% | -50% | - |
Operating Expenses | 59.88M | 54.05M | 57.23M | 79.23M | 77.95M | 38.03M | 29.47M | 4.82M | 4.23M | 3.95M |
OpEx % of Revenue | 937.27% | 37021.92% | - | - | 19584.67% | 1301.4% | 589380% | 48220% | 84600% | - |
Selling, General & Admin | 14.8M | 19.92M | 18.9M | 26.54M | 27.56M | 13.14M | 12.22M | 4.46M | 2.87M | 2.71M |
SG&A % of Revenue | 231.62% | 13642.47% | - | - | 6925.63% | 449.76% | 244380% | 44600% | 57340% | - |
Research & Development | 45.08M | 34.13M | 38.33M | 52.7M | 49.64M | 25.02M | 16.28M | 362K | 1.36M | 1.44M |
R&D % of Revenue | 705.65% | 23379.45% | - | - | 12473.12% | 856.19% | 325580% | 3620% | 27260% | - |
Other Operating Expenses | 465K | 0 | 0 | 0 | 740K | -133K | 971K | 0 | 0 | -193K |
Operating Income | -53.49M▲ 0% | -53.91M▼ 0.8% | -57.86M▼ 7.3% | -80.36M▼ 38.9% | -77.55M▲ 3.5% | -35.1M▲ 54.7% | -34.27M▲ 2.4% | -4.81M▲ 86.0% | -4.22M▲ 12.2% | -4.14M▲ 0% |
Operating Margin % | -837.27% | -36921.92% | - | - | -19484.67% | -1201.4% | -685340% | -48120% | -84500% | -138166.63% |
Operating Income Growth % | 67.64% | -0.77% | -7.33% | -38.89% | 3.5% | 54.73% | 2.39% | 85.96% | 12.2% | - |
EBITDA | -53.12M | -53.33M | -57.23M | -79.23M | -74.95M | -32.35M | -31.95M | -4.81M | -4.22M | -4.11M |
EBITDA Margin % | -831.49% | -36529.45% | - | - | -18832.16% | -1106.98% | -639040% | -48100% | -84360% | -136983.33% |
EBITDA Growth % | 67.81% | -0.39% | -7.31% | -38.45% | 5.4% | 56.84% | 1.22% | 84.95% | 12.31% | 0.28% |
D&A (Non-Cash Add-back) | 369K | 573K | 629K | 1.13M | 2.6M | 2.76M | 2.31M | 2K | 7K | 7.5K |
EBIT | -53.49M | -53.91M | -117.8M | -79.98M | -77.56M | -34.58M | -33.22M | -4.68M | -4.22M | -4.12M |
Net Interest Income | 0 | 0 | 0 | 0 | -1.19M | -3.15M | -1.92M | 0 | 0 | 0 |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 830K | 0 | 0 | 0 | 1.19M | 3.15M | 1.92M | 0 | 0 | 0 |
Other Income/Expense | -830K | 789K | -59.94M | 385K | -1.2M | -2.63M | -873K | 133K | 49K | 36K |
Pretax Income | -54.32M▲ 0% | -53.12M▲ 2.2% | -117.8M▼ 121.8% | -79.98M▲ 32.1% | -78.75M▲ 1.5% | -37.73M▲ 52.1% | -35.14M▲ 6.9% | -4.68M▲ 86.7% | -4.18M▲ 10.8% | -4.11M▲ 0% |
Pretax Margin % | -850.26% | -36381.51% | - | - | -19786.68% | -1291.24% | -702800% | -46790% | -83520% | -136966.67% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -54.32M▲ 0% | -53.12M▲ 2.2% | -117.8M▼ 121.8% | -79.98M▲ 32.1% | -78.75M▲ 1.5% | -37.73M▲ 52.1% | -35.14M▲ 6.9% | -4.68M▲ 86.7% | -4.18M▲ 10.8% | -4.11M▲ 0% |
Net Margin % | -850.26% | -36381.51% | - | - | -19786.68% | -1291.24% | -702800% | -46790% | -83520% | -136966.67% |
Net Income Growth % | 67.14% | 2.22% | -121.77% | 32.11% | 1.53% | 52.09% | 6.86% | 86.68% | 10.75% | -0.93% |
Net Income (Continuing) | -54.32M | -53.12M | -117.8M | -79.98M | -78.75M | -37.73M | -35.14M | -4.68M | -4.18M | -4.11M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -59.50▲ 0% | -55.44▲ 6.8% | -158.90▼ 186.6% | -56.42▲ 64.5% | -53.80▲ 4.6% | -25.97▲ 51.7% | -21.97▲ 15.4% | -2.92▲ 86.7% | -2.20▲ 24.7% | -2.11▲ 0% |
EPS Growth % | 68.71% | 6.82% | -186.62% | 64.49% | 4.64% | 51.73% | 15.4% | 86.71% | 24.66% | 14.57% |
EPS (Basic) | -59.50 | -55.52 | -158.90 | -56.42 | -53.80 | -25.97 | -21.97 | -2.92 | -2.20 | - |
Diluted Shares Outstanding | 912.92K | 956.72K | 1.12M | 1.4M | 1.43M | 1.45M | 1.6M | 1.6M | 1.95M | 1.95M |
Basic Shares Outstanding | 912.92K | 956.72K | 1.12M | 1.4M | 1.43M | 1.45M | 1.6M | 1.6M | 1.95M | 1.95M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TCRT Balance Sheet
Alaunos Therapeutics, Inc. (TCRT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 90.78M | 84.28M | 105.49M | 130.59M | 78.83M | 53.8M | 8.26M | 2.75M | 1.99M | 970K |
Cash & Short-Term Investments | 70.95M | 61.73M | 79.74M | 115.07M | 76.05M | 39.06M | 6.06M | 1.09M | 1.39M | 354K |
Cash Only | 70.95M | 61.73M | 79.74M | 115.07M | 76.05M | 39.06M | 6.06M | 1.09M | 1.39M | 354K |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 19K | 1.86M | 3.33M | 4.67M | 1.11M | 4K | 1K | 5K | 3K | 0 |
Days Sales Outstanding | 1.09 | 4.66K | - | - | 1.02K | 0.5 | 73 | 182.5 | 219 | 152.08 |
Inventory | 0 | 0 | 0 | 0 | 0 | 13.94M | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 20.69M | 0 | 0 | 1.67M | 799K | 2.2M | 1.66M | 600K | 616K |
Total Non-Current Assets | 14.82M | 10.77M | 3.62M | 15.76M | 16.03M | 11.14M | 2K | 0 | 978K | 913K |
Property, Plant & Equipment | 1.21M | 1.1M | 3.38M | 14.88M | 15.36M | 10.6M | 2K | 0 | 91K | 82K |
Fixed Asset Turnover | 5.28x | 0.13x | - | - | 0.03x | 0.28x | 2.50x | - | 0.05x | 0.04x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 104K | 105K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 13.51M | 9.56M | 240K | 875K | 673K | 542K | 0 | 0 | 887K | 831K |
Total Assets | 105.61M▲ 0% | 95.05M▼ 10.0% | 109.11M▲ 14.8% | 146.34M▲ 34.1% | 94.86M▼ 35.2% | 64.94M▼ 31.5% | 8.26M▼ 87.3% | 2.75M▼ 66.7% | 2.97M▲ 7.7% | 1.88M▲ 0% |
Asset Turnover | 0.06x | 0.00x | - | - | 0.00x | 0.04x | 0.00x | 0.00x | 0.00x | 0.00x |
Asset Growth % | -0.7% | -9.99% | 14.8% | 34.12% | -35.18% | -31.55% | -87.28% | -66.66% | 7.66% | 2.6% |
Total Current Liabilities | 20.86M | 9.48M | 12.53M | 18.37M | 16.04M | 24.17M | 1.96M | 692K | 813K | 595K |
Accounts Payable | 4.42M | 707K | 906K | 960K | 1.37M | 1.39M | 616K | 516K | 613K | 400K |
Days Payables Outstanding | - | - | 525.74 | 310.64 | - | - | 46.81 | - | - | 1.26K |
Short-Term Debt | 0 | 0 | 0 | 0 | 8.6M | 17.32M | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 6.39M | 13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2.06M | 6.63M | 1.91M | 13.28M | 3.65M | 3.74M | 1.3M | 0 | 0 | 195K |
Current Ratio | 4.35x | 8.89x | 8.42x | 7.11x | 4.91x | 2.23x | 4.22x | 3.98x | 2.45x | 1.63x |
Quick Ratio | 4.35x | 8.89x | 8.42x | 7.11x | 4.91x | 1.65x | 4.22x | 3.98x | 2.45x | 1.63x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.11K |
Total Non-Current Liabilities | 37.56M | 4K | 1.58M | 4M | 20.77M | 2.22M | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 16.25M | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 1.58M | 4M | 4.52M | 2.19M | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2.42M | 0 | 0 | 0 | -1K | 28K | 0 | 0 | 0 | 0 |
Total Liabilities | 202.41M | 9.49M | 14.1M | 22.36M | 36.81M | 26.38M | 1.96M | 692K | 813K | 595K |
Total Debt | 0 | 0 | 2.35M | 4.81M | 30.09M | 20.07M | 0 | 0 | 0 | 0 |
Net Debt | -70.95M | -61.73M | -77.39M | -110.25M | -45.96M | -18.99M | -6.06M | -1.09M | -1.39M | -354K |
Debt / Equity | - | - | 0.02x | 0.04x | 0.52x | 0.52x | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.09x |
Interest Coverage | -64.45x | - | - | - | -65.23x | -10.96x | -17.29x | - | - | - |
Total Equity | -96.81M▲ 0% | 85.56M▲ 188.4% | 95.01M▲ 11.0% | 123.98M▲ 30.5% | 58.06M▼ 53.2% | 38.55M▼ 33.6% | 6.31M▼ 83.6% | 2.06M▼ 67.3% | 2.15M▲ 4.4% | 1.29M▲ 0% |
Equity Growth % | -25.24% | 188.39% | 11.04% | 30.49% | -53.17% | -33.59% | -83.64% | -67.29% | 4.36% | 26.08% |
Book Value per Share | -106.04 | 89.43 | 84.85 | 88.71 | 40.62 | 26.63 | 3.94 | 1.29 | 1.11 | 0.66 |
Total Shareholders' Equity | -96.81M | 85.56M | 95.01M | 123.98M | 58.06M | 38.55M | 6.31M | 2.06M | 2.15M | 1.29M |
Common Stock | 143K | 161K | 182K | 215K | 216K | 240K | 16K | 2K | 2K | 2K |
Retained Earnings | -712.44M | -566.33M | -684.13M | -764.1M | -842.85M | -880.63M | -915.77M | -920.45M | -924.62M | -925.63M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -143.99M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TCRT Cash Flow Statement
Alaunos Therapeutics, Inc. (TCRT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -54.67M | -49.46M | -40.85M | -57.01M | -61.47M | -29.23M | -30.14M | -4.97M | -2.87M | -3.13M |
Operating CF Margin % | -855.67% | -33874.66% | - | - | -15444.22% | -1000.41% | -602840% | -49710% | -57380% | - |
Operating CF Growth % | 6.27% | 9.53% | 17.39% | -39.55% | -7.81% | 52.44% | -3.11% | 83.51% | 42.29% | 23.44% |
Net Income | -54.32M | -53.12M | -117.8M | -79.98M | -78.75M | -37.73M | -35.14M | -4.68M | -4.18M | -4.11M |
Depreciation & Amortization | 369K | 575K | 629K | 1.13M | 2.6M | 2.76M | 2.31M | 2K | 7K | 15K |
Stock-Based Compensation | 8.45M | 7.53M | 7.34M | 6.83M | 10.77M | 3.53M | 2.8M | 435K | 414K | 402K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.29M | -158K | 60.75M | 0 | 771K | 1.34M | 6.14M | 0 | 413K | 498K |
Working Capital Changes | -10.46M | -4.29M | 8.22M | 15.01M | 3.14M | 870K | -6.25M | -729K | 473K | 66K |
Change in Receivables | 2K | -1.84M | -1.47M | -1.33M | 3.56M | 1.11M | 3K | -4K | 2K | 2K |
Change in Inventory | 0 | 1.53M | 1.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 4.26M | -3.71M | 199K | 54K | 274K | -25K | -773K | -100K | 97K | -430K |
Cash from Investing | -737K | -459K | -284K | -9.78M | -3.32M | -193K | 1.35M | 0 | -98K | -98K |
Capital Expenditures | -737K | -459K | -284K | -9.78M | -3.32M | -216K | -197K | 0 | -98K | -98K |
CapEx % of Revenue | 11.54% | 314.38% | - | - | 834.92% | 7.39% | 3940% | - | 1960% | 3266.67% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -737K | 0 | 0 | 0 | 0 | 23K | 1.54M | 0 | 0 | 0 |
Cash from Financing | 45.3M | 40.31M | 59.15M | 102.12M | 25.78M | 6.37M | -18.14M | 0 | 3.26M | 3.26M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 25M | -8.33M | -18.11M | 0 | 0 | 0 |
Equity Issued (Net) | 45.21M | 45.48M | 5.43M | 101.68M | 0 | 14.68M | 92K | 0 | 3.26M | 3.26M |
Dividends Paid | 0 | -17M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -2.06M | -1.62M | -653K | 0 | 0 | -45K | 0 | 0 | 0 | 0 |
Other Financing | 88K | 11.83M | 53.72M | 442K | 776K | 21K | -125K | 0 | 0 | 0 |
Net Change in Cash | -10.11M▲ 0% | -9.61M▲ 5.0% | 18.01M▲ 287.5% | 35.33M▲ 96.1% | -39.02M▼ 210.4% | -23.06M▲ 40.9% | -46.93M▼ 103.5% | -4.97M▲ 89.4% | 294K▲ 105.9% | 35K▲ 0% |
Free Cash Flow | -55.41M▲ 0% | -49.92M▲ 9.9% | -41.14M▲ 17.6% | -66.79M▼ 62.4% | -64.79M▲ 3.0% | -29.45M▲ 54.5% | -30.34M▼ 3.0% | -4.97M▲ 83.6% | -2.97M▲ 40.3% | -3.23M▲ 0% |
FCF Margin % | -867.21% | -34189.04% | - | - | -16279.15% | -1007.8% | -606780% | -49710% | -59340% | -107533.3% |
FCF Growth % | 5.89% | 9.91% | 17.59% | -62.36% | 2.99% | 54.55% | -3.03% | 83.62% | 40.31% | 15.68% |
FCF per Share | -60.69 | -52.17 | -36.74 | -47.79 | -45.33 | -20.34 | -18.97 | -3.10 | -1.52 | -1.66 |
FCF Conversion (FCF/Net Income) | 1.01x | 0.93x | 0.35x | 0.71x | 0.78x | 0.77x | 0.86x | 1.06x | 0.69x | 0.79x |
Interest Paid | 0 | 0 | 0 | 0 | 630K | 2.17M | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TCRT Key Ratios
Alaunos Therapeutics, Inc. (TCRT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -62.08% | -130.47% | -73.04% | -86.52% | -78.11% | -156.66% | -111.8% | -198.1% | -165.94% |
Return on Invested Capital (ROIC) | - | - | -209.35% | -384.53% | -450.45% | -166.31% | -259.45% | -593.1% | -364.22% | -371.3% |
Gross Margin | 100% | 100% | - | - | 100% | 100% | -95960% | 100% | 100% | -6333.33% |
Net Margin | -850.26% | -36381.51% | - | - | -19786.68% | -1291.24% | -702800% | -46790% | -83520% | -136966.67% |
Debt / Equity | - | - | 0.02x | 0.04x | 0.52x | 0.52x | - | - | - | 0.00x |
Interest Coverage | -64.45x | - | - | - | -65.23x | -10.96x | -17.29x | - | - | - |
FCF Conversion | 1.01x | 0.93x | 0.35x | 0.71x | 0.78x | 0.77x | 0.86x | 1.06x | 0.69x | 0.79x |
Revenue Growth | -6.88% | -97.71% | -100% | - | - | 634.17% | -99.83% | 100% | -50% | -70% |
Related:TCRT Dividend History·TCRT Revenue History·TCRT Price History·TCRT P/E History·TCRT Financial Ratios·TCRT Institutional Holders
TCRT SEC Filings & Documents
Alaunos Therapeutics, Inc. (TCRT) SEC filings — annual & quarterly reports (10-K, 10-Q)
TCRT Frequently Asked Questions
Alaunos Therapeutics, Inc. (TCRT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Alaunos Therapeutics, Inc. (TCRT) reported $0.0M in revenue for fiscal year 2025. This represents a 74% increase from $0.0M in 2001.
Alaunos Therapeutics, Inc. (TCRT) saw revenue decline by 50.0% over the past year.
Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $4.1M for fiscal year 2025.
Dividend & Returns
Alaunos Therapeutics, Inc. (TCRT) has a return on equity (ROE) of -198.1%. Negative ROE indicates the company is unprofitable.
Alaunos Therapeutics, Inc. (TCRT) had negative free cash flow of $3.2M in fiscal year 2025, likely due to heavy capital investments.